[Zhou Jun] a large number of Chinese patent medicine and clinical emergency medicine have raised their prices; there are problems with the vaccine; Yunnan Baiyao is not afraid to question and starts 50.8 billion actions

Recently, the list of 17 department level leaders of the state health insurance administration of the State Administration of medicine and information technology was released, and a list of department level leaders of the state health insurance administration was circulated on the Internet According to the report, Yan Qinghui is to be the director of the office of the State Medical Security Bureau, Wang Wenjun is to be the director of the planning, finance and laws and regulations of the State Medical Security Bureau, Wang Fanglin is to be the director of the treatment and Security Department of the State Medical Security Bureau, Xiong Xianjun is to be the director of the medical service management department of the State Medical Security Bureau (at the level of the Department), Zhong Dongbo is to be the medical price and bidding procurement department of the State Medical Security Bureau Huang Huabo, director of the fund supervision department of the State Medical Security Bureau, and Wei zuobao, director of the personnel department of the State Medical Security Bureau On November 1, the State Food and Drug Administration issued guidance on the construction of drug information traceability system It clearly pointed out that we should speed up the construction of drug information traceability system and strengthen the exchange and sharing of traceability information in the direction of "one thing, one code, and the same tracking" With the introduction of this policy, the construction of drug traceability system, which has been stagnated for two years, has been speeded up, and the whole process of drug production, circulation and operation has been traced and the whole chain of supervision has been realized On October 30, the official website of the State Drug Administration issued the work procedure for the review and approval of clinically urgent overseas new drugs It is clearly pointed out that the varieties reviewed and approved by the special channel are only used for the treatment of rare diseases; for the prevention and treatment of serious life-threatening diseases, and there is no effective treatment or prevention means; for the prevention and treatment of serious life-threatening diseases, and drugs with obvious clinical advantages (new drugs listed in the United States, European Union or Japan but not listed in China in the past decade) As soon as the policy was implemented, CDE released the first batch of overseas new drugs urgently needed in clinical practice, including 40 kinds of overseas new drugs such as J & J's siltuximab and Lilly's ixekizumab 51 heavyweight new drugs carry out the verification of clinical data Once passed, they will be put on the market on October 30 The food and drug audit and inspection center of the State Food and Drug Administration issued an announcement It plans to carry out on-site verification of 51 drug clinical trial data self-examination and verification varieties, such as Tianshili Zhidong granules, xinlitai's sitafloxacin tablets, Qilu pharmaceutical's lenalidomide capsules, and Hunan Kelun's gefitinib tablets As early as July 22, 2015, the state launched the drug clinical trial data verification system, which indicates that if the relevant enterprises have prepared the declared product data fully, once the clinical data is verified, the products can obtain the "privilege" of marketing Roche Diagnostics China, the hot spot of the enterprise, will be replaced The successor will perform his duties in February of the next year On November 2, Roche Diagnostics China said to the public that Huang boxing, general manager of Roche Diagnostics China, will retire in March 2019 At the same time, it is announced that Yao Guoliang, general manager of Roche Diagnostics Korea, will take over the post of general manager of Roche Diagnostics China from February 1, 2019 It is reported that Yao Guoliang graduated from the Chinese University of Hong Kong in 1992, joined Roche Diagnostics Hong Kong company the next year, joined collier Hong Kong company in 1999 as sales manager, returned to Roche Diagnostics China in 2002, successively served as regional director, head of professional diagnosis department and organization diagnosis department, and was promoted to general manager of Roche Diagnostics South Korea in 2015 On October 31, Lizhu Pharmaceutical Group Co., Ltd issued a notice saying that on October 30, 2018, the 201-2 refining workshop of Lizhu group (Ningxia) Pharmaceutical Co., Ltd., a subsidiary of Lizhu pharmaceutical, had a fire disaster After that, the company immediately called the police and started the emergency plan The fire was effectively controlled and put out, and there were no casualties in the workshop It is worth mentioning that Lizhu group (Ningxia) Pharmaceutical Co., Ltd achieved an operating revenue of 628.3772 million yuan in 2017, accounting for 7.37% of the company's audited operating revenue in 2017, and realized a net profit of 6.478 million yuan, accounting for 0.14% of the company's audited net profit in 2017 The company said the accident would not have a significant impact on the production, operation and performance of the parent company Yunnan Baiyao absorbed and merged the parent company of 50.8 billion yuan, and realized the overall listing of the group on November 1 Yunnan Baiyao issued a notice to merge Baiyao holdings by issuing shares to the three shareholders of Baiyao holdings, Yunnan SASAC, Xinhua capital and Jiangsu Yuyue It is reported that the initial consideration for the merger is expected to be 50.813 billion yuan After the completion of the transaction, Baiyao holdings will be listed as a whole and will be cancelled as the merged party All its assets, liabilities and other rights and obligations will be inherited by the listed company At the same time, the equity ratio of listed companies is 25.10% for Yunnan SASAC, Xinhua and their concerted action, 8.19% for Yunnan hehe, 7.65% for China Ping An and 5.58% for Jiangsu Yuyue Another problem of influenza vaccine in other industries spread to 9 counties and cities on October 31 According to CCTV news, Taiwan Health Department 29 received a notice from Kaohsiung Health Bureau, and found a influenza vaccine with white suspension The batch of vaccine was produced by Taiwan Guoguang company, totaling more than 82000, and distributed to nine counties and cities, including Kaohsiung, Taichung, Jiayi and Tainan Among them, Kaohsiung has hit 8900, while other counties and cities are still under statistics At present, vaccination of the same batch has been suspended and sealed On November 2, Taiji Group announced that the factory price of Huoxiang Zhengqi oral liquid would be increased by 11% on average from November 1, 2018 due to the increase of cost and expenses It is reported that in 2017, Huoxiang Zhengqi oral liquid earned 1.35 billion yuan (including tax) Now the retail price of Taiji Huoxiang Zhengqi oral liquid is about 20 yuan If factory prices rise, retail prices will rise In addition, there are media reports that in recent years, a number of enterprises have announced the price increase of Chinese patent medicine For example, Jilin Aodong announced that since September 15, 2018, the retail price of 10ml * 10 pieces of Anshen brain tonic solution, a product of its own, will be adjusted to 32 yuan / box; foci pharmaceutical announced in March this year that the price of more than 100 products of the company will be increased in the whole line, and the factory price will be increased by 17.6% on average; dong'a gum will raise the price before March 20 this year, and the retail price of 250g dong'a gum will be adjusted to 1499 yuan, 48 pieces of compound donkey hide gelatin The selling price of pulp is adjusted to 499 yuan In this regard, some people in the industry think that the main reason for several price increases of Chinese patent medicine is that the loss caused by the price increase of raw materials in the early stage is too large, the cost of manpower and materials increases, and the quality supervision of Chinese herbal medicine becomes more and more strict However, the price rising trend has not only swept over Chinese patent medicine, but also a large number of clinical emergency medicine For example, recently reported by the media, noradrenaline has risen to 27 yuan a piece; dephosphorization has increased 70.3 times compared with the lowest price; aminoacetic acid has increased 72.3 times compared with the lowest price; m-hydroxyamine has increased 30.9 times compared with the lowest price More medical reports, the price of Cediland rose from a few yuan last year to 90 yuan a piece, and the price of iodophosphatidine injection rose from 8 yuan a piece to 100 yuan a piece Information source: yaozhi.com, Yaozhi elite club, Yaozhi news, State Drug Administration, Cyprian blue, health information bureau, medical representatives and other statements: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.